Skip to main content

Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments Proceedings of a Workshop (2020) / Chapter Skim
Currently Skimming:

5 Final Thoughts
Pages 43-46

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 43...
... should be en sured in biomarker studies to avoid incorrectly assuming a "one-size-fits-all" approach and potentially exacerbating health disparities (Nitkin)
Read the entire page →
From page 44...
... The panel included Betty Diamond, director of the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research; Sarah Morris, chief of the Adult Psychopathology and Psychosocial Intervention Research Branch at the National Institutes of Mental Health; Ralph Nitkin, deputy director for the National Center for Medical Rehabilitation Research at NIH's National Institute of Child Health and Human Development; and Ira Shoulson, professor of neurology, pharmacology, and medicine at the University of Rochester School of Medicine. Potential Use of Biomarkers Various types of biomarkers were highlighted throughout the workshop, including molecular, chemical, and systemic -- showing the breadth of potential biomarkers that researchers can study when looking for indicators to assist in more accurate diagnostic, prognostic, or treatment determinations.
Read the entire page →
From page 45...
... Continued Challenges Diamond called attention to the potential for being wrong, asking what are the risks to individuals or to society? This comment also echoed Peterson's previous remarks about the need to grapple with the risk of false positives and false negatives and understand what the risk of being wrong with biomarker assessment will be in a clinical context or in a disability application.
Read the entire page →
From page 46...
... Using tools and technology such as machine learning, he said, and by listening to patients and pairing their subjective reports with objective clinical information can help clinicians further determine a patient's disease progress. Shoulson also thought it would be useful if biomarkers related highly to function.
Read the entire page →

Key Terms

  • law remains
  • false positives
  • substantial gainful
  • positive findings
  • currently validated

  • gainful activity
  • validated biomarkers
  • false negatives
  • remains tenuous
  • using tools

  • security law
  • disease progress
  • comparison subjects
  • rochester school
  • biomarker studies

  • betty diamond
  • highlighted throughout
  • incorrectly assuming
  • help clinicians
  • intervention research

  • discover relationships
  • suggested exploring
  • nitkin noted
  • systemic redefinition
  • cause health

  • included betty
  • previous remarks
  • help understand
  • machine learning
  • child health


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.